Literature DB >> 27616458

The magnitude of cytokine production by stimulated CD56+ cells is associated with early stages of systemic sclerosis.

Marta Cossu1, Lenny van Bon2, Stefan Nierkens3, Chiara Bellocchi4, Alessandro Santaniello4, Harry Dolstra5, Lorenzo Beretta4, Timothy R D J Radstake6.   

Abstract

Immune activation is a hallmark of systemic sclerosis (SSc). However, the immunological alterations that occur in preclinical and non-fibrotic SSc and that differentiate these subjects from those with primary Raynaud's phenomenon (PRP) or healthy controls (HC) are poorly defined. We isolated CD56+ (NK/NKT-like) cells from HC, patients with PRP, early SSc (EaSSc) and definite SSc without skin or lung fibrosis. Cytokine production upon different activating stimuli was measured via a multiplex immuno assay. Clearly discriminative patterns among the different stages of SSc were most markedly observed after TLR1/2 stimulation, with increased IL-6, TNF-α and MIP-1α/CCL3 production in definite SSc patients as compared to HC and/or PRP. Initial alterations were observed in EaSSc patients with an intermediate secretion pattern between HC/PRP and definite SSc. CD56+ cells from patients at different stages of SSc differentially respond to TLR stimulation, highlighting the relevance of natural immunity in the developmental and pre-fibrotic SSc. Copyright Â
© 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD56(+) cells; Cytokines; Early systemic sclerosis; Systemic sclerosis; Toll like receptors

Mesh:

Substances:

Year:  2016        PMID: 27616458     DOI: 10.1016/j.clim.2016.09.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  10 in total

1.  Systemic sclerosis: The future is CD56-bright.

Authors:  Caroline Barranco
Journal:  Nat Rev Rheumatol       Date:  2016-10-06       Impact factor: 20.543

2.  [Application of lymphocytes test in peripheral blood of patients with systemic sclerosis during the treatment].

Authors:  X B Ma; X W Zhang; R L Jia; Y Gao; H J Liu; Y F Liu; Y N Li
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-18

Review 3.  Precursors to Systemic Sclerosis and Systemic Lupus Erythematosus: From Undifferentiated Connective Tissue Disease to the Development of Identifiable Connective Tissue Diseases.

Authors:  Leonardo Martin Calderon; Janet E Pope
Journal:  Front Immunol       Date:  2022-05-05       Impact factor: 8.786

4.  Haematological Malignancies in Systemic Sclerosis Patients: Case Reports and Review of the World Literature.

Authors:  M Colaci; D Giuggioli; C Vacchi; C Ferri
Journal:  Case Rep Rheumatol       Date:  2017-05-04

Review 5.  Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective.

Authors:  Marta Cossu; Lorenzo Beretta; Petra Mosterman; Maria J H de Hair; Timothy R D J Radstake
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

Review 6.  NK Cells in Autoimmune Diseases: Protective or Pathogenic?

Authors:  Meifang Liu; Shujuan Liang; Cai Zhang
Journal:  Front Immunol       Date:  2021-03-12       Impact factor: 7.561

Review 7.  Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?

Authors:  Anca Cardoneanu; Alexandra Maria Burlui; Luana Andreea Macovei; Ioana Bratoiu; Patricia Richter; Elena Rezus
Journal:  Biomedicines       Date:  2022-01-29

Review 8.  Predicting the Progression of Very Early Systemic Sclerosis: Current Insights.

Authors:  Chiara Bellocchi; Augustine Chung; Elizabeth R Volkmann
Journal:  Open Access Rheumatol       Date:  2022-09-15

9.  Natural Killer Cells Exhibit a Peculiar Phenotypic Profile in Systemic Sclerosis and Are Potent Inducers of Endothelial Microparticles Release.

Authors:  Audrey Benyamine; Jérémy Magalon; Florence Sabatier; Luc Lyonnet; Stéphane Robert; Chloé Dumoulin; Sophie Morange; Karin Mazodier; Gilles Kaplanski; Martine Reynaud-Gaubert; Pascal Rossi; Françoise Dignat-George; Brigitte Granel; Pascale Paul
Journal:  Front Immunol       Date:  2018-07-18       Impact factor: 7.561

Review 10.  Innate Immunity in Systemic Sclerosis Fibrosis: Recent Advances.

Authors:  Paoline Laurent; Vanja Sisirak; Estibaliz Lazaro; Christophe Richez; Pierre Duffau; Patrick Blanco; Marie-Elise Truchetet; Cécile Contin-Bordes
Journal:  Front Immunol       Date:  2018-07-23       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.